1887

Chapter 111 : Circulating Tumor Cells as an Analytical Tool in the Management of Patients with Cancer

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $30.00

Preview this chapter:
Zoom in
Zoomout

Circulating Tumor Cells as an Analytical Tool in the Management of Patients with Cancer, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555818722/9781555818715_CH111-1.gif /docserver/preview/fulltext/10.1128/9781555818722/9781555818715_CH111-2.gif

Abstract:

Circulating tumor cells (CTC), first described in 1869 as cells in the blood identical to those of the cancer itself (1), originate from the primary tumor or metastatic deposits after intravasation through the tumor vasculature by mechanisms that are not completely understood (Fig. 1) (2). Although most CTC die in the circulation, a proportion of them have the ability to spread, seed, and proliferate in distant sites to form secondary metastases (3) (estimated to be 0.05%) or to reestablish in the organ of origin to form new tumors (4), as demonstrated in short-term proliferation experiments (3, 5). First described by Paget in 1889, in his “seed and soil” hypothesis (6), the process of metastatic dissemination is driven by chemokines and integrins specific to the tumor type and by the adhesive interactions of the CTC with the vasculature and extracellular matrix components (4, 7–9). As an example, β4 integrin signaling promotes tumor cell adhesion to the endothelium through ErbB2-mediated vascular endothelial growth factor secretion and has been involved in metastatic development (10). Additionally, CTC have the ability to secrete stem cell-like factors to promote proliferation and self-renewal (11, 12). Microembolic clusters of CTC, isolated by a variety of techniques, are associated with a particularly poor prognosis, which may be related to the enhanced activation of survival pathways by cellular contact and to mechanical capture in the microvasculature, further enabling metastasis formation (13, 14).

Citation: Danila D, Scher H, Fleisher M. 2016. Circulating Tumor Cells as an Analytical Tool in the Management of Patients with Cancer, p 1051-1061. In Detrick B, Schmitz J, Hamilton R (ed), Manual of Molecular and Clinical Laboratory Immunology, Eighth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818722.ch111
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Image of FIGURE 1
FIGURE 1

CTC in the process of metastatic progression. Tumor cells transition from the primary or metastatic site into the circulation to establish secondary sites. (Reprinted from reference with permission of the publisher.)

Citation: Danila D, Scher H, Fleisher M. 2016. Circulating Tumor Cells as an Analytical Tool in the Management of Patients with Cancer, p 1051-1061. In Detrick B, Schmitz J, Hamilton R (ed), Manual of Molecular and Clinical Laboratory Immunology, Eighth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818722.ch111
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 2
FIGURE 2

CTC in patients with cancer. Sampling of CTC by phlebotomy at the time that treatment is being considered has the potential to provide tumor material for molecular profiling of biomarkers informative of tumor sensitivity to the targeted therapy being considered. FISH, fluorescence hybridization. (Reprinted from reference with permission of the publisher.)

Citation: Danila D, Scher H, Fleisher M. 2016. Circulating Tumor Cells as an Analytical Tool in the Management of Patients with Cancer, p 1051-1061. In Detrick B, Schmitz J, Hamilton R (ed), Manual of Molecular and Clinical Laboratory Immunology, Eighth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818722.ch111
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of FIGURE 3
FIGURE 3

Immunofluorescence and cytometry assay by use of high-throughput multiparametric imaging systems for detection of tumor-specific markers in the peripheral blood mononucleated cell fraction for patients with metastatic cancer. Immunostaining for cytokeratin (red) and the nucleus (DAPI; blue) separates morphologically distinct tumor cells from surrounding white blood cells stained by CD45 (green). (Reprinted from reference with permission of the publisher.)

Citation: Danila D, Scher H, Fleisher M. 2016. Circulating Tumor Cells as an Analytical Tool in the Management of Patients with Cancer, p 1051-1061. In Detrick B, Schmitz J, Hamilton R (ed), Manual of Molecular and Clinical Laboratory Immunology, Eighth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818722.ch111
Permissions and Reprints Request Permissions
Download as Powerpoint

References

/content/book/10.1128/9781555818722.ch111
1. Ashworth T. 1869. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aust Med J 14:146149.
2. Danila DC, Pantel K, Fleisher M, Scher HI. 2011. Circulating tumors cells as biomarkers: progress toward biomarker qualification. Cancer J 17:438450.[CrossRef].[PubMed]
3. Muller V, Stahmann N, Riethdorf S, Rau T, Zabel T, Goetz A, Janicke F, Pantel K. 2005. Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res 11:36783685.[CrossRef].[PubMed]
4. Kim MY, Oskarsson T, Acharyya S, Nguyen DX, Zhang XH, Norton L, Massagué J. 2009. Tumor self-seeding by circulating cancer cells. Cell 139:13151326.[CrossRef].[PubMed]
5. Stott SL, Hsu CH, Tsukrov DI, Yu M, Miyamoto DT, Waltman BA, Rothenberg SM, Shah AM, Smas ME, Korir GK, Floyd FP Jr, Gilman AJ, Lord JB, Winokur D, Springer S, Irimia D, Nagrath S, Sequist LV, Lee RJ, Isselbacher KJ, Maheswaran S, Haber DA, Toner M. 2010. Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci U S A 107:1839218397.[CrossRef].[PubMed]
6. Paget S. 1889. The distribution of secondary growths in cancer of the breast. Lancet i:571573.[CrossRef]
7. Fidler IJ. 2003. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer 3:453458.[CrossRef].[PubMed]
8. Gupta GP, Massagué J. 2006. Cancer metastasis: building a framework. Cell 127:679695.[CrossRef].[PubMed]
9. Ruoslahti E, Giancotti FG. 1989. Integrins and tumor cell dissemination. Cancer Cells 1:119126.[PubMed]
10. Fan J, Cai B, Zeng M, Hao Y, Giancotti FG, Fu BM. 2011. Integrin β4 signaling promotes mammary tumor cell adhesion to brain microvascular endothelium by inducing ErbB2-mediated secretion of VEGF. Ann Biomed Eng 39:22232241.[CrossRef].[PubMed]
11. Alix-Panabières C, Vendrell JP, Pellé O, Rebillard X, Riethdorf S, Müller V, Fabbro M, Pantel K. 2007. Detection and characterization of putative metastatic precursor cells in cancer patients. Clin Chem 53:537539.[CrossRef].[PubMed]
12. Alix-Panabières C, Vendrell JP, Slijper M, Pellé O, Barbotte E, Mercier G, Jacot W, Fabbro M, Pantel K. 2009. Full-length cytokeratin-19 is released by human tumor cells: a potential role in metastatic progression of breast cancer. Breast Cancer Res 11:R39.[CrossRef].[PubMed]
13. Krebs MG, Sloane R, Priest L, Lancashire L, Hou JM, Greystoke A, Ward TH, Ferraldeschi R, Hughes A, Clack G, Ranson M, Dive C, Blackhall FH. 2011. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol 29:15561563.[CrossRef].[PubMed]
14. Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, Smith MR, Kwak EL, Digumarthy S, Muzikansky A, Ryan P, Balis UJ, Tompkins RG, Haber DA, Toner M. 2007. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450:12351239.[CrossRef].[PubMed]
15. Riethdorf S, Wikman H, Pantel K. 2008. Review: biological relevance of disseminated tumor cells in cancer patients. Int J Cancer 123:19912006.[CrossRef].[PubMed]
16. Pantel K, Alix-Panabières C, Riethdorf S. 2009. Cancer micrometastases. Nat Rev Clin Oncol 6:339351.[CrossRef].[PubMed]
17. Schindlbeck C, Andergassen U, Hofmann S, Jückstock J, Jeschke U, Sommer H, Friese K, Janni W, Rack B. 2013. Comparison of circulating tumor cells (CTC) in peripheral blood and disseminated tumor cells in the bone marrow (DTC-BM) of breast cancer patients. J Cancer Res Clin Oncol 139:10551062.[CrossRef].[PubMed]
18. Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, Schlimok G, Diel IJ, Gerber B, Gebauer G, Pierga JY, Marth C, Oruzio D, Wiedswang G, Solomayer EF, Kundt G, Strobl B, Fehm T, Wong GY, Bliss J, Vincent-Salomon A, Pantel K. 2005. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353:793802.[CrossRef].[PubMed]
19. Weckermann D, Polzer B, Ragg T, Blana A, Schlimok G, Arnholdt H, Bertz S, Harzmann R, Klein CA. 2009. Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer. J Clin Oncol 27:15491556.[CrossRef].[PubMed]
20. Köllermann J, Weikert S, Schostak M, Kempkensteffen C, Kleinschmidt K, Rau T, Pantel K. 2008. Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment. J Clin Oncol 26:49284933.[CrossRef].[PubMed]
21. Pierga JY, Bonneton C, Vincent-Salomon A, de Cremoux P, Nos C, Blin N, Pouillart P, Thiery JP, Magdelenat H. 2004. Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients. Clin Cancer Res 10:13921400.[PubMed].[CrossRef]
22. Bidard FC, Vincent-Salomon A, Gomme S, Nos C, de Rycke Y, Thiery JP, Sigal-Zafrani B, Mignot L, Sastre-Garau X, Pierga JY. 2008. Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse. Clin Cancer Res 14:33063311.[CrossRef].[PubMed]
23. Scher HI, Pantel K. 2009. Bone marrow aspiration for disseminated tumor cell detection: a must-have test or is the jury still out? J Clin Oncol 27:15311533.[CrossRef].[PubMed]
24. Hüsemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E, Forni G, Eils R, Fehm T, Riethmüller G, Klein CA. 2008. Systemic spread is an early step in breast cancer. Cancer Cell 13:5868.[CrossRef].[PubMed]
25. Bartkowiak K, Wieczorek M, Buck F, Harder S, Moldenhauer J, Effenberger KE, Pantel K, Peter-Katalinic J, Brandt BH. 2009. Two-dimensional differential gel electrophoresis of a cell line derived from a breast cancer micrometastasis revealed a stem/progenitor cell protein profile. J Proteome Res 8:20042014.[PubMed].[CrossRef]
26. Uhr JW, Pantel K. 2011. Controversies in clinical cancer dormancy. Proc Natl Acad Sci U S A 108:1239612400.[CrossRef].[PubMed]
27. Lin WC, Rajbhandari N, Wagner KU. 2014. Cancer cell dormancy in novel mouse models for reversible pancreatic cancer: a lingering challenge in the development of targeted therapies. Cancer Res 74:21382143.[CrossRef].[PubMed]
28. Borovski T, De Sousa e Melo F, Vermeulen L, Medema JP. 2011. Cancer stem cell niche: the place to be. Cancer Res 71:634639.[CrossRef].[PubMed]
29. Thiery JP, Sleeman JP. 2006. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7:131142.[CrossRef].[PubMed]
30. Kalluri R, Weinberg RA. 2009. The basics of epithelial-mesenchymal transition. J Clin Invest 119:14201428.[CrossRef].[PubMed]
31. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA. 2008. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133:704715.[CrossRef].[PubMed]
32. Polyak K, Weinberg RA. 2009. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 9:265273.[CrossRef].[PubMed]
33. Thurm H, Ebel S, Kentenich C, Hemsen A, Riethdorf S, Coith C, Wallwiener D, Braun S, Oberhoff C, Janicke F, Pantel K. 2003. Rare expression of epithelial cell adhesion molecule on residual micrometastatic breast cancer cells after adjuvant chemotherapy. Clin Cancer Res 9:25982604.[PubMed]
34. Schneck H, Gierke B, Uppenkamp F, Behrens B, Niederacher D, Stoecklein NH, Templin MF, Pawlak M, Fehm T, Neubauer H Disseminated Cancer Cell Network (DCC Net) Duesseldorf. 2015. EpCAM-independent enrichment of circulating tumor cells in metastatic breast cancer. PLoS One 10:e0144535. doi:10.1371/journal.pone.0144535.[CrossRef].[PubMed] http://dx.doi.org/doi:10.1371/journal.pone.0144535
35. Mikolajczyk SD, Millar LS, Tsinberg P, Coutts SM, Zomorrodi M, Pham T, Bischoff FZ, Pircher TJ. 2011. Detection of EpCAM-negative and cytokeratin-negative circulating tumor cells in peripheral blood. J Oncol 2011:252361.[CrossRef].[PubMed]
36. Huang RY, Wong MK, Tan TZ, Kuay KT, Ng AH, Chung VY, Chu YS, Matsumura N, Lai HC, Lee YF, Sim WJ, Chai C, Pietschmann E, Mori S, Low JJ, Choolani M, Thiery JP. 2013. An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530). Cell Death Dis 4:e915.[CrossRef].[PubMed]
37. Danila DC, Fleisher M, Scher HI. 2011. Circulating tumor cells as biomarkers in prostate cancer. Clin Cancer Res 17:39033912.[CrossRef].[PubMed]
38. Yu M, Stott S, Toner M, Maheswaran S, Haber DA. 2011. Circulating tumor cells: approaches to isolation and characterization. J Cell Biol 192:373382.[CrossRef].[PubMed]
39. Stott SL, Lee RJ, Nagrath S, Yu M, Miyamoto DT, Ulkus L, Inserra EJ, Ulman M, Springer S, Nakamura Z, Moore AL, Tsukrov DI, Kempner ME, Dahl DM, Wu CL, Iafrate AJ, Smith MR, Tompkins RG, Sequist LV, Toner M, Haber DA, Maheswaran S. 2010. Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med 2:25ra23.[CrossRef].[PubMed]
40. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AG, Uhr JW, Terstappen LW. 2004. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 10:68976904.[CrossRef].[PubMed]
41. Budd GT, Cristofanilli M, Ellis MJ, Stopeck A, Borden E, Miller MC, Matera J, Repollet M, Doyle GV, Terstappen LW, Hayes DF. 2006. Circulating tumor cells versus imaging—predicting overall survival in metastatic breast cancer. Clin Cancer Res 12:64036409.[CrossRef].[PubMed]
42. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF. 2004. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351:781791.[CrossRef].[PubMed]
43. Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, Doyle GV, Matera J, Allard WJ, Miller MC, Fritsche HA, Hortobagyi GN, Terstappen LW. 2005. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 23:14201430.[CrossRef].[PubMed]
44. Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, Matera J, Allard WJ, Doyle GV, Terstappen LW. 2006. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 12:42184224.[CrossRef].[PubMed]
45. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC, Doyle GV, Tissing H, Terstappen LW, Meropol NJ. 2008. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 26:32133221.[CrossRef].[PubMed]
46. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse MA, Mitchell E, Miller MC, Doyle GV, Tissing H, Terstappen LW, Meropol NJ. 2009. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol 20:12231229.[CrossRef].[PubMed]
47. Danila DC, Heller G, Gignac GA, Gonzalez-Espinoza R, Anand A, Tanaka E, Lilja H, Schwartz L, Larson S, Fleisher M, Scher HI. 2007. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 13:70537058.[CrossRef].[PubMed]
48. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta KJ, Raghavan D. 2008. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14:63026309.[CrossRef].[PubMed]
49. Scher HI, Jia X, de Bono JS, Fleisher M, Pienta KJ, Raghavan D, Heller G. 2009. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol 10:233239.[CrossRef].[PubMed]
50. Coumans FA, Doggen CJ, Attard G, de Bono JS, Terstappen LW. 2010. All circulating EpCAM+CK+CD45− objects predict overall survival in castration-resistant prostate cancer. Ann Oncol 21:18511857.[CrossRef].[PubMed]
51. Shaffer DR, Leversha MA, Danila DC, Lin O, Gonzalez-Espinoza R, Gu B, Anand A, Smith K, Maslak P, Doyle GV, Terstappen LW, Lilja H, Heller G, Fleisher M, Scher HI. 2007. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res 13:20232029.[CrossRef].[PubMed]
52. Attard G, Swennenhuis JF, Olmos D, Reid AH, Vickers E, A'Hern R, Levink R, Coumans F, Moreira J, Riisnaes R, Oommen NB, Hawche G, Jameson C, Thompson E, Sipkema R, Carden CP, Parker C, Dearnaley D, Kaye SB, Cooper CS, Molina A, Cox ME, Terstappen LW, de Bono JS. 2009. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 69:29122918.[CrossRef].[PubMed]
53. Ulmer A, Schmidt-Kittler O, Fischer J, Ellwanger U, Rassner G, Riethmuller G, Fierlbeck G, Klein CA. 2004. Immunomagnetic enrichment, genomic characterization, and prognostic impact of circulating melanoma cells. Clin Cancer Res 10:531537.[PubMed].[CrossRef]
54. Racila E, Euhus D, Weiss AJ, Rao C, McConnell J, Terstappen LW, Uhr JW. 1998. Detection and characterization of carcinoma cells in the blood. Proc Natl Acad Sci U S A 95:45894594.[PubMed].[CrossRef]
55. Scholtens TM, Schreuder F, Ligthart ST, Swennenhuis JF, Tibbe AG, Greve J, Terstappen LW. 2011. CellTracks TDI: an image cytometer for cell characterization. Cytometry A 79:203213.[CrossRef].[PubMed]
56. Bocsi J, Varga VS, Molnár B, Sipos F, Tulassay Z, Tárnok A. 2004. Scanning fluorescent microscopy analysis is applicable for absolute and relative cell frequency determinations. Cytometry A 61:18.[CrossRef].[PubMed]
57. Weight RM, Viator JA. 2014. Detection of circulating tumor cells by photoacoustic flowmetry. Methods Mol Biol 1102:655663.[CrossRef].[PubMed]
58. Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J, Cook K, Stepansky A, Levy D, Esposito D, Muthuswamy L, Krasnitz A, McCombie WR, Hicks J, Wigler M. 2011. Tumour evolution inferred by single-cell sequencing. Nature 472:9094.[CrossRef].[PubMed]
59. Yaniv I, Cohen IJ, Stein J, Zilberstein J, Liberzon E, Atlas O, Grunshpan A, Sverdlov Y, Ash S, Zaizov R, Avigad S. 2004. Tumor cells are present in stem cell harvests of Ewings sarcoma patients and their persistence following transplantation is associated with relapse. Pediatr Blood Cancer 42:404409.[CrossRef].[PubMed]
60. Wong IH, Chan AT, Johnson PJ. 2000. Quantitative analysis of circulating tumor cells in peripheral blood of osteosarcoma patients using osteoblast-specific messenger RNA markers: a pilot study. Clin Cancer Res 6:21832188.[PubMed]
61. Dubois SG, Epling CL, Teague J, Matthay KK, Sinclair E. 2010. Flow cytometric detection of Ewing sarcoma cells in peripheral blood and bone marrow. Pediatr Blood Cancer 54:1318.[CrossRef].[PubMed]
62. Helzer KT, Barnes HE, Day L, Harvey J, Billings PR, Forsyth A. 2009. Circulating tumor cells are transcriptionally similar to the primary tumor in a murine prostate model. Cancer Res 69:78607866.[CrossRef].[PubMed]
63. Giordano A, Giuliano M, De Laurentiis M, Arpino G, Jackson S, Handy BC, Ueno NT, Andreopoulou E, Alvarez RH, Valero V, De Placido S, Hortobagyi GN, Reuben JM, Cristofanilli M. 2012. Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. Ann Oncol 23:11441150.[CrossRef].[PubMed]
64. Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, Inserra E, Diederichs S, Iafrate AJ, Bell DW, Digumarthy S, Muzikansky A, Irimia D, Settleman J, Tompkins RG, Lynch TJ, Toner M, Haber DA. 2008. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 359:366377.[CrossRef].[PubMed]
65. Harb W, Fan A, Tran T, Danila DC, Keys D, Schwartz M, Ionescu-Zanetti C. 2013. Mutational analysis of circulating tumor cells using a novel microfluidic collection device and qPCR assay. Transl Oncol 6:528538.[PubMed].[CrossRef]
66. Gleghorn JP, Pratt ED, Denning D, Liu H, Bander NH, Tagawa ST, Nanus DM, Giannakakou PA, Kirby BJ. 2010. Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody. Lab Chip 10:2729.[CrossRef].[PubMed]
67. Ozkumur E, Shah AM, Ciciliano JC, Emmink BL, Miyamoto DT, Brachtel E, Yu M, Chen PI, Morgan B, Trautwein J, Kimura A, Sengupta S, Stott SL, Karabacak NM, Barber TA, Walsh JR, Smith K, Spuhler PS, Sullivan JP, Lee RJ, Ting DT, Luo X, Shaw AT, Bardia A, Sequist LV, Louis DN, Maheswaran S, Kapur R, Haber DA, Toner M. 2013. Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci Transl Med 5:179ra47.[CrossRef].[PubMed]
68. Winer-Jones JP, Vahidi B, Arquilevich N, Fang C, Ferguson S, Harkins D, Hill C, Klem E, Pagano PC, Peasley C, Romero J, Shartle R, Vasko RC, Strauss WM, Dempsey PW. 2014. Circulating tumor cells: clinically relevant molecular access based on a novel CTC flow cell. PLoS One 9:e86717.[CrossRef].[PubMed]
69. Ramirez JM, Fehm T, Orsini M, Cayrefourcq L, Maudelonde T, Pantel K, Alix-Panabières C. 2014. Prognostic relevance of viable circulating tumor cells detected by EPISPOT in metastatic breast cancer patients. Clin Chem 60:214221.[CrossRef].[PubMed]
70. Alix-Panabières C, Rebillard X, Brouillet JP, Barbotte E, Iborra F, Segui B, Maudelonde T, Jolivet-Reynaud C, Vendrell JP. 2005. Detection of circulating prostate-specific antigen-secreting cells in prostate cancer patients. Clin Chem 51:15381541.[CrossRef].[PubMed]
71. Paris PL, Kobayashi Y, Zhao Q, Zeng W, Sridharan S, Fan T, Adler HL, Yera ER, Zarrabi MH, Zucker S, Simko J, Chen WT, Rosenberg J. 2009. Functional phenotyping and genotyping of circulating tumor cells from patients with castration resistant prostate cancer. Cancer Lett 277:164173.[CrossRef].[PubMed]
72. Shim S, Gascoyne P, Noshari J, Hale KS. 2011. Dynamic physical properties of dissociated tumor cells revealed by dielectrophoretic field-flow fractionation. Integr Biol (Camb) 3:850862.[CrossRef].[PubMed]
73. Gel M, Kimura Y, Kurosawa O, Oana H, Kotera H, Washizu M. 2010. Dielectrophoretic cell trapping and parallel one-to-one fusion based on field constriction created by a micro-orifice array. Biomicrofluidics 4:022808.[CrossRef].[PubMed]
74. Borgatti M, Altomare L, Abonnec M, Fabbri E, Manaresi N, Medoro G, Romani A, Tartagni M, Nastruzzi C, Di Croce S, Tosi A, Mancini I, Guerrieri R, Gambari R. 2005. Dielectrophoresis-based ‘lab-on-a-chip’ devices for programmable binding of microspheres to target cells. Int J Oncol 27:15591566.[PubMed]
75. Lecharpentier A, Vielh P, Perez-Moreno P, Planchard D, Soria JC, Farace F. 2011. Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer. Br J Cancer 105:13381341.[CrossRef].[PubMed]
76. Lin HK, Zheng S, Williams AJ, Balic M, Groshen S, Scher HI, Fleisher M, Stadler W, Datar RH, Tai YC, Cote RJ. 2010. Portable filter-based microdevice for detection and characterization of circulating tumor cells. Clin Cancer Res 16:50115018.[CrossRef].[PubMed]
77. Zheng S, Lin HK, Lu B, Williams A, Datar R, Cote RJ, Tai YC. 2011. 3D microfilter device for viable circulating tumor cell (CTC) enrichment from blood. Biomed Microdevices 13:203213.[CrossRef].[PubMed]
78. Farace F, Massard C, Vimond N, Drusch F, Jacques N, Billiot F, Laplanche A, Chauchereau A, Lacroix L, Planchard D, Le Moulec S, André F, Fizazi K, Soria JC, Vielh P. 2011. A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. Br J Cancer 105:847853.[CrossRef].[PubMed]
79. Adams DL, Martin SS, Alpaugh RK, Charpentier M, Tsai S, Bergan RC, Ogden IM, Catalona W, Chumsri S, Tang CM, Cristofanilli M. 2014. Circulating giant macrophages as a potential biomarker of solid tumors. Proc Natl Acad Sci U S A 111:35143519.[CrossRef].[PubMed]
80. Marrinucci D, Bethel K, Kolatkar A, Luttgen MS, Malchiodi M, Baehring F, Voigt K, Lazar D, Nieva J, Bazhenova L, Ko AH, Korn WM, Schram E, Coward M, Yang X, Metzner T, Lamy R, Honnatti M, Yoshioka C, Kunken J, Petrova Y, Sok D, Nelson D, Kuhn P. 2012. Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers. Phys Biol 9:016003.[CrossRef].[PubMed]
81. Ghossein RA, Scher HI, Gerald WL, Kelly WK, Curley T, Amsterdam A, Zhang ZF, Rosai J. 1995. Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications. J Clin Oncol 13:11951200.[PubMed]
82. Helo P, Cronin AM, Danila DC, Wenske S, Gonzalez-Espinoza R, Anand A, Koscuiszka M, Väänänen RM, Pettersson K, Chun FK, Steuber T, Huland H, Guillonneau BD, Eastham JA, Scardino PT, Fleisher M, Scher HI, Lilja H. 2009. Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with CellSearch assay and association with bone metastases and with survival. Clin Chem 55:765773.[CrossRef].[PubMed]
83. Iinuma H, Watanabe T, Mimori K, Adachi M, Hayashi N, Tamura J, Matsuda K, Fukushima R, Okinaga K, Sasako M, Mori M. 2011. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes’ stage B and C colorectal cancer. J Clin Oncol 29:15471555.[CrossRef].[PubMed]
84. Xi L, Nicastri DG, El-Hefnawy T, Hughes SJ, Luketich JD, Godfrey TE. 2007. Optimal markers for real-time quantitative reverse transcription PCR detection of circulating tumor cells from melanoma, breast, colon, esophageal, head and neck, and lung cancers. Clin Chem 53:12061215.[CrossRef].[PubMed]
85. Reinholz MM, Kitzmann KA, Tenner KS, Hillman DW, Dueck AC, Hobday TJ, Northfelt DW, Moreno-Aspitia A, Roy V, Laplant B, Allred JB, Stella PJ, Lingle W, Perez EA. 2011. Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast cancer patients enrolled in North Central Cancer Treatment Group (NCCTG) trials, N0234/336/436/437. Clin Cancer Res 7:71837193.
86. Sieuwerts AM, Mostert B, Bolt-de Vries J, Peeters D, de Jongh FE, Stouthard JM, Dirix LY, van Dam PA, Van Galen A, de Weerd V, Kraan J, van der Spoel P, Ramirez-Moreno R, van Deurzen CH, Smid M, Yu JX, Jiang J, Wang Y, Gratama JW, Sleijfer S, Foekens JA, Martens JW. 2011. mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients. Clin Cancer Res 17:36003618.[CrossRef].[PubMed]
87. Zhao S, Liu Y, Zhang Q, Li H, Zhang M, Ma W, Zhao W, Wang J, Yang M. 2011. The prognostic role of circulating tumor cells (CTCs) detected by RT-PCR in breast cancer: a meta-analysis of published literature. Breast Cancer Res Treat 130:809816.[CrossRef].[PubMed]
88. Yoon SO, Kim YT, Jung KC, Jeon YK, Kim BH, Kim CW. 2011. TTF-1 mRNA-positive circulating tumor cells in the peripheral blood predict poor prognosis in surgically resected non-small cell lung cancer patients. Lung Cancer 71:209216.[CrossRef].[PubMed]
89. Ignatiadis M, Kallergi G, Ntoulia M, Perraki M, Apostolaki S, Kafousi M, Chlouverakis G, Stathopoulos E, Lianidou E, Georgoulias V, Mavroudis D. 2008. Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer. Clin Cancer Res 14:25932600.[CrossRef].[PubMed]
90. Nakagawa T, Martinez SR, Goto Y, Koyanagi K, Kitago M, Shingai T, Elashoff DA, Ye X, Singer FR, Giuliano AE, Hoon DS. 2007. Detection of circulating tumor cells in early-stage breast cancer metastasis to axillary lymph nodes. Clin Cancer Res 13:41054110.[CrossRef].[PubMed]
91. Danila DC, Anand A, Schultz N, Heller G, Wan M, Sung CC, Dai C, Khanin R, Fleisher M, Lilja H, Scher HI. 2014. Analytic and clinical validation of a prostate cancer-enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survival. Eur Urol 65:11911197.[CrossRef].[PubMed]
92. Schleiermacher G, Peter M, Oberlin O, Philip T, Rubie H, Mechinaud F, Sommelet-Olive D, Landman-Parker J, Bours D, Michon J, Delattre O Société Française d'Oncologie Pédiatrique. 2003. Increased risk of systemic relapses associated with bone marrow micrometastasis and circulating tumor cells in localized Ewing tumor. J Clin Oncol 21:8591.[PubMed].[CrossRef]
93. Aktas B, Bankfalvi A, Heubner M, Kimmig R, Kasimir-Bauer S. 2013. Evaluation and correlation of risk recurrence in early breast cancer assessed by Oncotype DX(®), clinicopathological markers and tumor cell dissemination in the blood and bone marrow. Mol Clin Oncol 1:10491054.[CrossRef].[PubMed]
94. Danila DC, Anand A, Sung CC, Heller G, Leversha MA, Cao L, Lilja H, Molina A, Sawyers CL, Fleisher M, Scher HI. 2011. TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. Eur Urol 60:897904.[CrossRef].[PubMed]
95. Andreopoulou E, Yang LY, Rangel KM, Reuben JM, Hsu L, Krishnamurthy S, Valero V, Fritsche HA, Cristofanilli M. 2012. Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veridex CellSearch™ system. Int J Cancer 130:15901597.[CrossRef].[PubMed]
96. Talasaz AH, Powell AA, Huber DE, Berbee JG, Roh KH, Yu W, Xiao W, Davis MM, Pease RF, Mindrinos MN, Jeffrey SS, Davis RW. 2009. Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device. Proc Natl Acad Sci U S A 106:39703975.[CrossRef].[PubMed]
97. Wendel M, Bazhenova L, Boshuizen R, Kolatkar A, Honnatti M, Cho EH, Marrinucci D, Sandhu A, Perricone A, Thistlethwaite P, Bethel K, Nieva J, Heuvel M, Kuhn P. 2012. Fluid biopsy for circulating tumor cell identification in patients with early- and late-stage non-small cell lung cancer: a glimpse into lung cancer biology. Phys Biol 9:016005.[CrossRef].[PubMed]
98. Biomarkers Definitions Working Group. 2001. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69:8995.[CrossRef].[PubMed]
99. FDA/NCI/CMS Oncology Biomarker Qualification Initiative. 30 April 2009. Memorandum of Understanding between the FDA, NCI, and CMS for the FDA/NCI/CMS Oncology Biomarker Qualification Initiative. Document MOU 225-06-8001. http://www.fda.gov/AboutFDA/PartnershipsCollaborations/MemorandaofUnderstanding MOUs/DomesticMOUs/ucm115681.htm. Accessed 16 March 2011.
100. Altar CA. 2008. The Biomarkers Consortium: on the critical path of drug discovery. Clin Pharmacol Ther 83:361364.[CrossRef].[PubMed]
101. Botteri E, Sandri MT, Bagnardi V, Munzone E, Zorzino L, Rotmensz N, Casadio C, Cassatella MC, Esposito A, Curigliano G, Salvatici M, Verri E, Adamoli L, Goldhirsch A, Nolè F. 2010. Modeling the relationship between circulating tumour cells number and prognosis of metastatic breast cancer. Breast Cancer Res Treat 122:211217.[CrossRef].[PubMed]
102. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, Seely L, Morris MJ, Danila DC, Humm J, Larson S, Fleisher M, Sawyers CL Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium. 2010. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 375:14371446.[CrossRef].[PubMed]
103. Veridex LLC. 2008. CellSearch Circulating Tumor Cell Kit Premarket Notification—Expanded Indications for Use—Metastatic Prostate Cancer. http://www.accessdata.fda.gov/cdrh_docs/pdf7/K073338.pdf.
104. Gonen M, Heller G. 2005. Concordance probability and discriminative power of proportional hazards regression. Biometrika 92:965970.[CrossRef]
105. Scher HI, Heller G, Molina A, Attard G, Danila DC, Jia X, Peng W, Sandhu SK, Olmos D, Riisnaes R, McCormack R, Burzykowski T, Kheoh T, Fleisher M, Buyse M, de Bono JS. 2015. Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer. J Clin Oncol 33:13481355.[CrossRef].[PubMed]
106. Koyanagi K, O'Day SJ, Boasberg P, Atkins MB, Wang HJ, Gonzalez R, Lewis K, Thompson JA, Anderson CM, Lutzky J, Amatruda TT, Hersh E, Richards J, Weber JS, Hoon DS. 2010. Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma. Clin Cancer Res 16:24022408.[CrossRef].[PubMed]
107. Leversha MA, Han J, Asgari Z, Danila DC, Lin O, Gonzalez-Espinoza R, Anand A, Lilja H, Heller G, Fleisher M, Scher HI. 2009. Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. Clin Cancer Res 15:20912097.[CrossRef].[PubMed]
108. Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J. 2014. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371:10281038.[CrossRef].[PubMed]
109. de Bono JS, Attard G, Adjei A, Pollak MN, Fong PC, Haluska P, Roberts L, Melvin C, Repollet M, Chianese D, Connely M, Terstappen LW, Gualberto A. 2007. Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin Cancer Res 13:36113616.[CrossRef].[PubMed]
110. Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L, Ryan C, Smith S, Scher H, Scardino P, Reuter V, Gerald WL. 2004. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 164:217227.[CrossRef].[PubMed]
111. Scher HI, Kelly WK. 1993. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 11:15661572.[PubMed]
112. Yang MJ, Chiu HH, Wang HM, Yen LC, Tsao DA, Hsiao CP, Chen YF, Wang JY, Lin SR. 2010. Enhancing detection of circulating tumor cells with activating KRAS oncogene in patients with colorectal cancer by weighted chemiluminescent membrane array method. Ann Surg Oncol 17:624633.[CrossRef].[PubMed]
113. Punnoose EA, Atwal SK, Spoerke JM, Savage H, Pandita A, Yeh RF, Pirzkall A, Fine BM, Amler LC, Chen DS, Lackner MR. 2010. Molecular biomarker analyses using circulating tumor cells. PLoS One 5:e12517.[CrossRef].[PubMed]
114. Nakazawa M, Lu C, Chen Y, Paller CJ, Carducci MA, Eisenberger MA, Luo J, Antonarakis ES. 2015. Serial blood-based analysis of AR-V7 in men with advanced prostate cancer. Ann Oncol 26:18591865.[CrossRef].[PubMed]
115. Pantel K, Riethdorf S. 2009. Pathology: are circulating tumor cells predictive of overall survival? Nat Rev Clin Oncol 6:190191.[CrossRef].[PubMed]

Tables

Generic image for table
TABLE 1

Context of use for baseline CTC count as a prognostic biomarker for overall survival for patients with metastatic disease from the Immunicon 38 trials

Citation: Danila D, Scher H, Fleisher M. 2016. Circulating Tumor Cells as an Analytical Tool in the Management of Patients with Cancer, p 1051-1061. In Detrick B, Schmitz J, Hamilton R (ed), Manual of Molecular and Clinical Laboratory Immunology, Eighth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818722.ch111

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error